Acute lymphoblastic leukemia cytotoxic acute lymphocytic leukemia. Medical search. Frequent questions

Vibecotamab(XmAb-14045) is under development for the treatment of hematologic malignancies such as relapsed/refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia, blastic plasmacytoid dendritic cell neoplasm, myelodysplastic syndrome and chronic myeloid leukemia. (pharmaceutical-technology.com)
Outcomes for the treatment of chronic myeloid leukemia (CML) have dramatically improved over the past 50 years. (lls.org)
hodgkin lymphoma in a case of chronic myeloid leukemia treated with tyrosine kinase inhibitors. (liverpool.ac.uk)
chronic myeloid leukemia (cml) is characterized by increased and unregulated proliferation of granulocytic lineage in the bone marrow and presence of these immature myeloid cells in the peripheral blood with presence of philadelphia (ph) chromosome. (liverpool.ac.uk)

In the context of relapsed and refractory childhood pre-B cell acute lymphoblastic leukemia (R/R B-ALL), CD19-targeting chimeric antigen receptor (CAR)-T cells often induce durable remissions, which requires the persistence of CAR-T cells. (nature.com)
CAR-T cells, which incorporate an antibody-derived extracellular receptor and T cell derived intracellular signaling domains, have shown convincing outcomes in certain types of leukemia and lymphoma, including commercial licensure of CD19 CAR-Ts for the treatment of relapsed/ refractory large B cell lymphoma and acute lymphoblastic leukemia. (bdbiosciences.com)
President and CEO Yoshihiko Hatanaka "Astellas") today announced that an application was submitted in Japan for the marketing authorization for bispecific CD19-directed CD3 T cell engager (BiTE ® ) antibody construct blinatumomab (Genetically Recombination) (generic name, development code: AMG 103, "blinatumomab") to treat relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). (astellas.com)
Improved outcomes for relapsed or refractory ALL patients calls for the development of drugs such as blinatumomab which demonstrate efficacy as a monotherapy and have mechanisms of action dissimilar to cytotoxic agents. (astellas.com)
Multidrug resistance parameters, tissue infiltration parameters, receptors for colony-stimulating factors (CSFr) and cell cycle parameters were analyzed using flow cytometry in 145, 109 initial and 36 relapsed or refractory, acute nonlymphoblastic leukemia (ANLL) patients to find out clinically more reliable functional parameters. (karger.com)
In December 2020, Precision reported encouraging interim clinical results for its Phase 1/2a study of patients with relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) and R/R B-cell Acute Lymphoblastic leukemia (B-ALL). (precisionbiosciences.com)
In a multicenter, single-arm, open-label phase 2 study on patients with relapsed or refractory B-precursor acute lymphoblastic leukemia, the distribution of any grade neurologic ir-AEs frequency was 52% among patients receiving blinatumomab, and grade 3 or 4 neurologic ir-AEs occurred in 11% and 2% patients, respectively [ 19 ]. (hindawi.com)
The complete remission rate (CR) in the treatment of recurrent/refractory B-cell acute lymphoblastic leukemia and B-cell lymphoma (R/R B-ALL)with CAR-T cell therapy is more than 90% and 50%, respectively [ 1 , 2 ]. (biomedcentral.com)

Vibecotamab is under clinical development by Xencor and currently in Phase I for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia). (pharmaceutical-technology.com)
According to GlobalData, Phase I drugs for B-Cell Acute Lymphocytic Leukemia (B-Cell Acute Lymphoblastic Leukaemia) have a 90% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. (pharmaceutical-technology.com)
The estimated overall incidence of acute lymphoblastic leukaemia (ALL) and lymphoblastic lymphoma in Europe is 1.28 per 100 000 individuals annually, with significant age-related variations (0.53 at 45-54 years, ∼1.0 at 55-74 years and 1.45 at 75-99 years). (medscape.com)
Acute lymphoblastic leukaemia in Noonan syndrome. (lu.se)

The technique has also shown preliminarily promising outcomes in B cell acute lymphoblastic leukemia (B-ALL), B cell non-Hodgkin's lymphoma (B-NHL), chronic lymphocytic leukemia (CLL), Hodgkin's lymphoma and multiple myeloma in clinical trials targeting CD19, CD20, CD22, CD30 and B-cell maturation antigen (BCMA), with many more under investigation. (bdbiosciences.com)
In this review, we aim to summarize the composition of CAR-T cell and its application in the treatment of acute lymphocytic leukemia (ALL), chronic lymphocytic leukemia (CLL), non-Hodgkin's lymphoma (NHL), Hodgkin's lymphoma (HL), multiple myeloma (MM), and acute myeloid leukemia (AML). (hindawi.com)

However, relapsed ALL remains a leading cause of childhood death despite intensive cytotoxic chemotherapy often including allogeneic bone marrow transplantation. (nature.com)
I. To evaluate the tolerability of azacitidine in addition to Interfant-06 standard chemotherapy in infants with newly diagnosed acute lymphoblastic leukemia (ALL) with KMT2A gene rearrangement (KMT2A-R). (iu.edu)
Nearly every breakthrough in cancer treatment has emerged from our support of leukemia research, from chemotherapy to groundbreaking CAR T-cell immunotherapy. (lls.org)
The five-year survival rate for a child with leukemia 50 years ago was a dismal 3%, but with the advent of combination chemotherapy as standard of care in the 1960s, increasing understanding of the disease, and more recent discoveries of novel therapeutics, cures are now possible in children. (lls.org)

The Chronic Lymphocytic Leukemia Research Consortium defines a lymphoblast as "A lymphocyte that has become larger after being stimulated by an antigen. (wikipedia.org)
Prior allogeneic hematopoietic stem cell transplant (HSCT) or donor lymphocyte infusion within 6 months prior to enrollment, current acute graft versus host disease grade 2-4 by Glucksberg criteria or severity B-D by by International Bone Marrow Transplant Registry (IBMTR) index or history of severe (grade 3-4) acute graft versus host disease. (moffitt.org)
The most active T cell endogenous inhibitory pathway is the immunoglobulin superfamily such as CD28/cytotoxic T lymphocyte antigen-4 (CTLA-4): B7-1/B7-2 receptor/ligand grouping, which plays a central role in coordinating immune responses [ 7 , 8 ]. (hindawi.com)
Ledbetter JA, Evans RL, Lipinski M, Cunningham-Rundles C, Good RA, Herzenberg LA. Evolutionary conservation of surface molecules that distinguish T lymphocyte helper/inducer and cytotoxic/suppressor subpopulations in mouse and man. (bdbiosciences.com)
Immune checkpoint inhibitors (ICIs) are antibodies that target crucial signaling pathways, such as programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1), and cytotoxic T-lymphocyte-associated protein 4 (CTLA-4), to improve the activation of T cells and enhance the immune response to cancer cells. (hindawi.com)

Although several subtypes of T-cell lymphoblastic leukemia/lymphoma exist, early T-cell precursor lymphoblastic leukemia (ETP-ALL) is the only subtype recognized as an entity in the revised 2016 WHO tumor classification. (medscape.com)
Non-ETP subtypes of T-cell lymphoblastic leukemia/lymphoma, in contrast, are associated with activating NOTCH1 mutations in over half of all patients and an additional 10% to 15% of cases have FBXW7 mutations, which also result in increased NOTCH signaling. (medscape.com)

Normally lymphoblasts are found in the bone marrow, but in acute lymphoblastic leukemia (ALL), lymphoblasts proliferate uncontrollably and are found in large numbers in the peripheral blood. (wikipedia.org)

Over the past 10 years, The Leukemia & Lymphoma Society (LLS) has invested more than $52 million to accelerate pioneering research in chronic lymphocytic leukemia (CLL), a blood cancer characterized by the development of too many white blood cells called lymphocytes. (lls.org)
Rapid detection of intracellular SH2D1A protein in cytotoxic lymphocytes from patients with X-linked lymphoproliferative disease and their family members. (lu.se)

CD19 appears to be expressed on myeloid leukemia cells, particularly those of monocytic lineage. (thermofisher.com)

B-lineage acute lymphoblastic leukemia (B-ALL) is the most common type of childhood cancer and mostly derives from immature B cells that carry the cell surface antigen CD19 (ref. 1 ). (nature.com)
Immature SP thymocytes undergo further differentiation to generate either MHC Class II restricted CD4 SP helper or MHC Class I restricted CD8 SP cytotoxic lineage cells [ 1 ] . (encyclopedia.pub)
Reprogramming is a promising treatment, which redifferentiates T-induced pluripotent stem cells (T-IPSCs) into naïve and cytotoxic T cells or dedifferentiates within their own lineage [ 13 ]. (hindawi.com)

[ 1 ] ETP-ALL frequently has mutations in RUNX1 and/or ETV6 in addition to genes that are more commonly associated with myeloid neoplasms and are otherwise rare in T-cell lymphoblastic leukemia/lymphoma (such as FLT3 , IDH1/2 , TET2 , and DNMT3A mutations). (medscape.com)
Mutations of FLT3, NRAS, KRAS, and PTPN11 are frequent and possibly mutually exclusive in high hyperdiploid childhood acute lymphoblastic leukemia. (lu.se)
PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. (lu.se)

Malignant lymphomas, which may regress following withdrawal of methotrexate, may occur in patients receiving low-dose methotrexate and, thus, may not require cytotoxic treatment. (nih.gov)
Engineered chimeric antigen receptor (CAR) T cell therapies (CAR-T) are now commercially available to treat certain leukemias and lymphomas. (bdbiosciences.com)
Lymphoblastic leukemias/lymphomas are neoplasms of precursor T cells and B cells or lymphoblasts. (medscape.com)
In the United States, lymphoblastic lymphoma is relatively rare, comprising only 2% of all non-Hodgkin lymphomas (NHLs). (medscape.com)

The receptor for CD19 is an important functional regulator of normal and malignant B cell proliferation, and is expressed in all B cell precursor leukemias. (thermofisher.com)
however, because lymphoblastic lymphoma and acute lymphoblastic leukemia (ALL) are known to represent the same disease entity, the World Health Organization (WHO) classification has unified these entities as precursor B-cell and T-cell lymphoblastic leukemia/lymphoma. (medscape.com)

The LLS mission: Cure leukemia, lymphoma, Hodgkin's disease and myeloma, and improve the quality of life of patients and their families. (lls.org)

Finally the dividing cells differentiate into effector cells, known as plasma cells (for B cells), cytotoxic T cells, and helper T cells. (wikipedia.org)
An exception was long-lived CAR-T cells in two adult individuals with a different cancer-chronic lymphocytic leukemia (CLL)-in whom anti-CD19 CAR-T cells have persisted for almost a decade thus far 7 . (nature.com)
Nonetheless, the general strategy for combatting cancer for some time has been a targeted version of what can be considered cellular poison: cytotoxic drugs that affect only rapidly-dividing cells. (harvard.edu)
The purpose of the study is to find out if an investigational drug called PRGN-3007 UltraCAR-T cells (PRGN-3007 T cells) can help people with ROR1-positive hematologic chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), acute lymphoblastic leukemia (ALL), diffuse large B-cell lymphoma (DLBCL) and solid tumor triple negative breast cancer (TNBC) malignancies. (moffitt.org)
CD4 cytotoxic T cells: an emerging effector arm of anti-tumor immunity. (cdc.gov)
CTLs) that produce cytokines and cytotoxic enzymes (perforin, granzyme B) that eliminate pathogens or target cells (including pathogen-infected host cells and tumor cells) and can develop into memory T cells ( Figure 1 ) [ 12 ] . (encyclopedia.pub)
Leukemia is a cancer of the early blood-forming cells and it usually begins in the bone marrow. (lls.org)
This blood cancer is divided into several groups based on whether the leukemia is fast growing (acute leukemias) or slower growing (chronic leukemias), and whether it starts in myeloid cells (myeloid or myelogenous leukemias) or lymphoid cells (lymphoblastic or lymphocytic leukemias). (lls.org)
Acute myeloid leukemia (AML) is an aggressive, rapidly-progressing disease in which the immature blood cells do not develop properly and grow uncontrollably. (lls.org)
In vitro , CD3 + CD8 + CD27 - CD28 - compared to CD3 + CD8 + CD27 + CD28 + CART cells displayed similar CD19 + target cell-specific cytotoxicity, but were hypoproliferative and produced less cytotoxic cytokines (IFN-γ and TNF-α). (frontiersin.org)
Human T-cell antigens deﬁned by monoclonal antibodies: The 65,000-dalton antigen of T cells (T65) is also found on chronic lymphocytic leukemia cells bearing surface immunoglobulin. (bdbiosciences.com)
In large cell lymphoma and leukemia cells involvement of body fluid this concept becomes less challenging. (cytojournal.com)
Large cell lymphoma and leukemia cells tend to have large size nuclei, less mature chromatin, and visible nucleoli with and without cytoplasmic vacuoles. (cytojournal.com)
Reducing or knocking down Class 1 MHC expression on allogeneic CAR T cells has been shown to reduce CAR T cell killing by cytotoxic T cells. (precisionbiosciences.com)

Genome-wide single-nucleotide polymorphism analysis in juvenile myelomonocytic leukemia identifies uniparental disomy surrounding the NF1 locus in cases associated with neurofibromatosis but not in cases with mutant RAS or PTPN11. (lu.se)
The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. (lu.se)

T-lymphoblastic lymphoma (T-LBL) accounts for 25-30% of childhood NHL and is closely related to T-lymphoblastic leukemia (T-ALL). (medscape.com)
Population-based attributes for Social Exclusion Index (SEI) and household size may be useful surrogate markers of early exposure to childhood infections, which has been found to decrease the risk of acute lymphoblastic leukemia (ALL). (medscape.com)

Compared to healthy controls (n=24), DLBCL patients (n=33) showed significant lymphopenia, due to low CD3 + CD4 + T helper and CD3 - CD56 + NK cell counts, while cytotoxic CD3 + CD8 + T cell counts were similar. (frontiersin.org)

It is an extended bi-specific monoclonal antibody which contains both tumor antigen binding domain CD123 and cytotoxic T-cell binding domain (CD3 binding domain). (pharmaceutical-technology.com)
Binding of a tumor antigen via the scFv activates the T cell in a major histocompatibility-independent manner which leads to a cytotoxic response [ 3 ]. (nature.com)
Leukemia phenotype studies have demonstrated that the earliest and broadest B cell restricted antigen is the CD19 antigen. (thermofisher.com)

Characterization of acute myeloid leukemia with PTPN11 mutation: the mutation is closely associated with NPM1 mutation but inversely related to FLT3/ITD. (lu.se)

The need for new treatments for AML remains urgent, which is why The Leukemia & Lymphoma Society (LLS) has invested approximately one quarter of its research doll. (lls.org)
The Leukemia & Lymphoma Society® (LLS) is a global leader in the fight against cancer. (lls.org)
The Leukemia & Lymphoma Society is a 501(c)(3) organization, and all monetary donations are tax deductible to the fullest extent allowed by tax laws. (lls.org)

This gene product is a bZIP protein, which was also identified as a cellular transcription factor that binds to an enhancer in the promoter of the T cell leukemia virus type 1 promoter. (cancerindex.org)

ANLL is also known as Acute Myeloid Leukemia. (lab-ally.com)

This is a rare type of leukemia where most of the blasts are megakaryoblastic. (lab-ally.com)
Clonal duplication of a germline PTPN11 mutation due to acquired uniparental disomy in acute lymphoblastic leukemia blasts from a patient with Noonan syndrome. (lu.se)

Many investigators have suggested that both lymphoblastic lymphoma and acute lymphoblastic leukemia (ALL) may be part of one clinical spectrum of a single malignant lymphoproliferative disorder . (medscape.com)

Methotrexate-induced lung disease, including acute or chronic interstitial pneumonitis, is a potentially dangerous lesion, which may occur acutely at any time during therapy and has been reported at low doses. (nih.gov)

Like other cytotoxic drugs, methotrexate may induce "tumor lysis syndrome" in patients with rapidly growing tumors. (nih.gov)
This case report demonstrates the acute onset of mania in a patient with no history of bipolar disorder , which putatively was precipitated by the use of intrathecal methotrexate in the treatment of acute lymphoblastic leukemia. (psychiatrictimes.com)

Most children with B-ALL can be cured through first-line treatment comprising combinations of cytotoxic agents. (nature.com)
Cytoxan is used for treatment of cancer with cytotoxic effect. (canadianfpharmacy.com)
Cytoxan belongs to the drugs for treatment of cancer with cytotoxic effect. (canadianfpharmacy.com)
Hairy cell leukemia (HCL) is a rare, slow-growing disease that responds to initial treatment. (lls.org)
After being evaluated by the psychiatric consult liaison (C-L) team, Charlie was started on olanzapine, which was titrated to 10 mg BID for treatment of acute manic and psychotic symptoms. (psychiatrictimes.com)
Patients who achieve a complete remission to initial treatment and then experience a cancer recurrence are said to have relapsed leukemia. (radiationoncologyassociates.co)

This persistence signature was also detected in two adult patients with chronic lymphocytic leukemia with decade-long remissions who received a different CD19 CAR-T cell product. (nature.com)
Lymphoblastic lymphoma is aggressive and progresses rapidly, presenting as stage IV disease in more than 70% of patients (see Staging). (medscape.com)
Larson RA, Sievers EL, Stadtmauer EA et al (2005) Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. (springer.com)
Chaque année, des milliers de volontaires, pour la plupart des patients, mais aussi des personnes en bonne santé, participent à nos études. (ottawaheart.ca)
patients may present with many years of symptoms or with acute, life-threatening disease. (medscape.com)

Its Plamotamab is a tumor-targeted antibody that contains both a CD20 binding domain and a cytotoxic T-cell binding domain (CD3). (pharmaceutical-technology.com)
B-Cell Acute Lymphoblastic Leukemia. (lab-ally.com)

While the ten year survival rates were less than 20% with the use of cytotoxic agents in the 1970's, and improved to 50% with bone marrow transplants, the biggest improvements occurred within the last 20 years after the approval of an oral therapy, known as imatinib. (lls.org)

Limiting the antibody-induced induction of immunosuppressive reactive oxygen species may improve the anti-leukemic efficacy of anti-CD20 therapy in chronic lymphocytic leukemia. (cusabio.com)

Leukemia makes up approroximately one third of all new blood cancer cases in the U.S. and Europe. (lls.org)
Leukemia is also the most common cancer in general in children and teens, accounting for almost one out of three cancers. (lls.org)

Lymphoblastic lymphoma is associated with exposure to radiation or pesticides and congenital or acquired immunosuppression and is more common in children and young adults. (medscape.com)

Foundations of the severe acute respiratory syndrome preparedness and response plan for healthcare facilities. (cdc.gov)
Investigation of a nosocomial outbreak of severe acute respiratory syndrome (SARS) in Toronto, Canada. (cdc.gov)

However, in vivo, it becomes necessary to enhance metabolic activity to maintain high invasion potential and cytotoxic function. (biomedcentral.com)

20% lymphoblasts in marrow), a diagnosis of lymphoblastic lymphoma is made. (medscape.com)

This module will provide learners with a succinct yet comprehensive review of each major cytotoxic chemotherapeutic drug class. (hoparx.org)

Anatomy30

Organisms8

Diseases53

Chemicals and Drugs78

Analytical, Diagnostic and Therapeutic Techniques and Equipment47

Phenomena and Processes51

Disciplines and Occupations1

Information Science6

Named Groups2

Health Care14

Chronic myeloid4

Refractory8

Leukaemia4

Multiple myeloma2

Chemotherapy4

Lymphocyte5

Subtypes2

Proliferate1

Lymphocytes2

Myeloid leukemia cells1

Lineage3

Mutations3

Lymphomas4

Precursor2

Hodgkin's1

Cells14

Juvenile Myelomon2

Childhood2

Helper1

Antigen3

FLT31

Lymphoma Society3

Protein1

ANLL1

Blasts2

Lymphoproliferative disorder1

Doses1

Methotrexate2

Treatment6

Patients5

Cell2

Bone1

Immunosuppressive1

Cancer2

Radiation1

Severe2

Metabolic1

Diagnosis1

Major1